October 12, 2021 5:23pm
I hope you’re stockpiling some “powder i.e., cash” in your portfolio
Pre-open indication results: 5 Hits and 0 MISS
My version of the session’s “indications” is about what you need to know; it’s what did happen after the opening, mid-day and to the close
An objective, fact and numbers-based narrative
The Dow closed DOWN -177.72 points (-0.34%); the S&P closed DOWN -10.54 points (-0.24%) while the Nasdaq closed DOWN -20.27 points (-0.14%)
Henry’omics:
All three (3) major U.S. stock indexes closed lower for a third 93rd) consecutive session Tuesday ahead of a key inflation reading and a kick-off to Q3 earnings season.
Interesting notes: Amgen (AMGN) lost 2.3% to an 18-month low. Shares have been stuck below their 50-day and 200-day lines since early August. J&J (JNJ) stock is trading near the bottom of a flat base with a 178.02 buy point. An FDA committee is slated to meet Friday to discuss the merits of a J&J Covid-19 booster shot.
Economic Data Docket: Job openings in August fell 659,000 to 10.4 million, according to the Labor Department’s latest Job Openings and Labor Turnover Survey.
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Tuesday opened positive at 26/6, 2 flats and 1 acquired, stayed positive at the mid-day at 21/12, 1 flat and 1 acquired, ending with a positive close of 7/24, 3 flats and 1 acquired;
- Monday opened positive at 18/15, 1 flat and 1 acquired, stayed positive at the mid-day at 24/8, 2 flats and 1 acquired, ending with a positive close of19/14, 1 flat and 1 acquired;
RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: is the sector running into a wall of resistance? There are a lot of headwinds out there.” … https://www.regmedinvestors.com/articles/12134
Pre-open indication results: 5 Hits: < Biostage (BSTG -$0.20); SELL into Strength: CRISPR Therapeutics (CRSP +$1.94), Editas Medicine (EDIT +$0.89), Intellia Therapeutics (NTLA +$2.15), ReNeuron (RENE.L +$2.50 after yesterday’s +$20.42)> and 0 MISS
Key Metric - volume:
- Sector volume was LOW with 7 of the 21-upside having higher than the 3-month average volume with INCREASED volume of 3 of 11-downside having higher than the 3-month average volume;
Largest upside volume:
- ReNeuron (RENE.L +$2.50– 641 7 shares traded),
- Adverum Biotechnologies (ADVM +$0.09 – 4.437 m shares traded),
Largest downside volume:
- Voyager Therapeutics (VYGR -$0.19 – 10.763 m shares traded)
There are clear winners and losers
Jumping with share pricing momentum (x of x):
- Fate Therapeutics (FATE +$2.52 after Monday’s +$1.62)
- ReNeuron (RENE.L +$2.50 after Monday’s +$20.70)
- Regenxbio (RGNX +$2.35 after Monday’s +$1.94),
- Intellia therapeutics (NTLA +$2.15 after Monday’s +$5.22),
- CRISPR Therapeutics (CRSP +$1.94 after Monday’s +$2.02),
- Ultragenyx (RARE +$1.80 after Monday’s -$0.65),
- Global Blood Therapeutics (GBT +$1.07 after Monday’s +$0.70),
- Editas Medicine (EDIT +$0.89),
- BioLife Solutions (BLFS +$0.59 after Monday’s -$0.52)
- bluebird bio (BLUE =$0.53 after Monday’s +$0.80),
Hammered in today’s market (1 of 11):
- Vericel (VCEL -$1.46 after Monday’s -$1.48)
- Alnylam Pharmaceuticals (ALNY -$1.09 after Monday’s +$0.83)
- Ionis Pharmaceuticals (IONS -$0.40 after Monday’s +$0.32),
- Biostage (-$0.20 after Monday’s $0.00),
- Voyager Therapeutics (VYGR -$0.19 after Monday’s -$0.75),
- Chinook therapeutics (KDNY -$0.140,
- Sangamo therapeutics (SGMO -$0.08),
- Verastem (VSTM -$0.08),
- Pluristem (PSTI -$0.04),
- AxoGen (AXGN -$0.02 after Tuesday’s -$0.09),
Closing Flat:
2 – Brainstorm Cell therapeutics (BCLI), Athersys (ATHX) and 1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday the IBB closed up +0.12% and XBI closed up +0.44%
- Monday, the IBB closed down -0.35% and XBI closed up +0.51%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was down -0.15 points or -0.75% at 19.85
- Monday was up +1.23 points or +6.55% at 20.00
October, the first month of Q3/21:
Tuesday closed positive with 21 advancers, 14 decliners, 2 flats and 1 acquired
Monday (10/11) closed positive with 19 advancers, 14 decliners, 1 flat and 1 acquired
The BOTTOM LINE: I’m still welcoming the upside but, warn of “harm” coming to share pricing.
And I am eyeing LPS (loss-per-share) muted returns for 2021 re quarterly releases.
There are a lot of headwinds out there as we embark on earnings, and traders will be looking for any and all indications of guidance — especially as the threat of slower growth looms large.
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
